Isolator technology is emerging, albeit slowly, as an alternative to classified space in the manufacture of pharmaceutical and biological products. Isolators’ principal value is a reduction in the ...
Isolator-based Grade A/ISO 5 architectures minimize operator interventions, enabling robust contamination control and compliance with EU GMP Annex 1, FDA guidance, PIC/S, and ISO 14644. Lyophilization ...
WuXi Biologics, a CDMO, launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi ...